[Antipsoriatic effect of dithranol (anthralin). 2].
D000818:Animals; D000873:Anthracenes / Q000627:therapeutic use*; D000875:Anthralin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004336:Drug Antagonism; D006801:Humans; D051379:Mice; D009154:Mutation / Q000187:drug effects; D009374:Neoplasms, Experimental / Q000139:chemically induced; D009696:Nucleic Acids / Q000378:metabolism; D009824:Ointments; D010101:Oxygen Consumption; D011565:Psoriasis / Q000188:drug therapy*; D015032:Zinc
D000873:Anthracenes; D009696:Nucleic Acids; D009824:Ointments; D015032:Zinc; D000875:Anthralin
Zur antipsoriatischen Wirkung von Dithranol (Anthralin). Zweiter Teil